logo

For the Inventor, By the Inventor

San Ramon, CA, United States of America

Jiang Zhu

This inventor holds 7 USPTO granted patents and 1 EPO patent. Top assignee: Principia Biopharma Inc.. Active years: 2020-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jiang Zhu. Retrieved from https://idiyas.com/inventor/jiang-zhu-u4ipu6tx

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7

% Patents Active = 85.7

 

Average Co-Inventor Count = 2.7

ph-index = 2

Forward Citations = 4(Granted Patents)


Company Filing History:

goldMedal7 out of 56 
 
Principia Biopharma Inc.
 patents

Years Active: 2020-2026

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents
1. 12673953 - Process for preparing an amorphous form of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (2026-07-07),
2. 12281120 - Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile (2025-04-21),
3. 12281110 - Processes for preparing an FGFR inhibitor (2025-04-21),
4. 11708370 - Solid forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (2023-07-25),
5. 11667641 - Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile (2023-06-06),
6. 10899760 - Processes for preparing an FGFR inhibitor (2021-01-26),
7. 10538518 - Processes for preparing an FGFR inhibitor (2020-01-21),

Title: Jiang Zhu: Innovator in Pharmaceutical Chemistry

Introduction

Jiang Zhu is a prominent inventor based in San Ramon, California, known for his significant contributions to pharmaceutical chemistry. With a total of six patents to his name, he has made remarkable advancements in the field of drug development.

Latest Patents

Jiang Zhu's latest patents include innovative processes for preparing an FGFR inhibitor. These processes involve the synthesis of 8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one and its polymorphs and/or salt forms. Additionally, he has disclosed crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile, along with pharmaceutical compositions and methods for inhibiting BTK.

Career Highlights

Jiang Zhu has established himself as a key figure in the pharmaceutical industry through his work at Principia Biopharma Inc. His expertise in drug formulation and development has led to significant breakthroughs in therapeutic options.

Collaborations

Jiang has collaborated with notable colleagues, including Mohammad Reza Masjedizadeh and Kolbot By, contributing to a dynamic research environment that fosters innovation.

Conclusion

Jiang Zhu's work exemplifies the impact of innovative thinking in pharmaceutical chemistry. His patents and collaborations continue to advance the field, showcasing his dedication to improving healthcare solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…